About UMGCC

2007 Fact Sheet

Overview:

Quick Facts

2,200	Admissions
30,000	Outpatient Visits
150	Clinical Trials
55	Attending Physicians
168	Researchers

The University of Maryland Marlene and Stewart Greenebaum Cancer Center is a national leader in offering innovative approaches to cancer diagnosis and treatment. With comprehensive programs for treating all types of cancer, we are a major referral center for patients throughout the state and region. As an academic cancer center, we have more than 160 scientists and clinical investigators conducting cutting-edge research, including clinical trials that enable patients to receive the latest therapies long before they become widely available.

All of our physicians and researchers are on the faculty of the University of Maryland School of Medicine or other professional schools of the University of Maryland, Baltimore.

Highlights:

Multidisciplinary Approach to Patient Care
Targeted, Minimally Invasive Therapies
Patient-Focused Outpatient Pavilion with Infusion Center and Chemotherapy Pharmacy
Specialized Inpatient Facilities, Including Bone Marrow/Stem Cell Transplant Unit
Full-time Patient Navigator
Strong Translational Research Program -- from Lab Bench to Patient Bedside
$40 Million in Research Funding

Advances in Patient Care:

Leader in providing less-invasive cancer treatment options for patients. Offers the latest advances in minimally invasive surgery as well as state-of-the-art radiation therapies and novel drug treatments.
Longstanding multidisciplinary approach to cancer care, with teams of specialists developing individualized treatment plans for each patient.
Leader in using "targeted" therapies that spare healthy tissue. First in Maryland to treat liver cancer patients with SIR-Spheres, microscopic radioactive beads delivered directly to tumors.
First in Maryland to offer treatment with Trilogy, the most powerful and precise radiation therapy system available.
Modern outpatient facility - the Roslyn and Leonard Stoler Pavilion - with infusion center, comfortable waiting area, flat-screen TVs and Internet access.
Patient navigator program to guide patients through the treatment process. Developed through unique partnership with the American Cancer Society.
Specialized inpatient facilities, including bone marrow/stem cell transplant unit and new, spacious private rooms for patients recovering from cancer surgery.
Consistently earns high ratings in patient satisfaction surveys for excellent and compassionate nursing care.
Outreach to thousands of uninsured Baltimore residents with free cancer screenings supported by the Maryland Cigarette Restitution Fund Program.

Research Advances:

Pioneered the development of a new class of breast cancer drugs now helping to save the lives of women worldwide. Angela H. Brodie, Ph.D., received top international honors for her discovery of aromatase inhibitors -- the most significant advance in treating breast cancer in a decade.
Active translational research program that moves scientific discoveries from the laboratory to the clinic. More than 450 patients enrolled annually in clinical trials.
Cancer vaccines, novel cancer-fighting agents and new combinations of surgery, radiation and chemotherapy are among the promising therapies being developed and offered to patients.
Leader in minority participation in clinical studies. More than 30 percent of participants are minorities, far exceeding the U.S. average of less than 10 percent.
National leader in IMRT (intensity modulated radiation therapy) to target tumors. Developed innovative software that cuts patients' treatment time in half.
State-of-the-art research facilities, with new proteomics laboratory to analyze proteins. Part of a major initiative to expand and renovate cancer research labs.
Major partnership with the state through the Maryland Cigarette Restitution Fund Program. Funds help strengthen research programs, expand clinical trials, buy equipment and recruit world-class scientists and cancer specialists.